Tradestie Institutional Equity Comparison Engine
KTTA vs CLYM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CLYM Overall Edge
CLYM Captures Institutional Edge (1โ0 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Momentum & Technical. Fundamentally, KTTA trades at N/M Forward P/E with 0.0% operating margin (+1498.1% YoY revenue) versus CLYM at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, KTTA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
KTTA N/M vs CLYM N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY +1498.1% vs +0.0%
Momentum & Technical Winner
CLYM
1Y +0.6% vs +399.5% ยท 52W Pos 11% vs 45%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
KTTA
NASDAQ
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap
$17.7M
1M Return
+7.52%
1Y Return
+0.59%
Forward P/E
N/M
Unified AI Score
42.1 / 100
HOLD
Tech 20.0
Fund 40.0
Flow 50.0
Mom 60.0
CLYM
NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.19
-0.97% 1D
Market Cap
$545.1M
1M Return
-12.81%
1Y Return
+399.46%
Forward P/E
N/M
Unified AI Score
43.7 / 100
HOLD
Tech 40.0
Fund 54.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
KTTA +0.59%
CLYM +399.46%
Spread: +398.87 pp (CLYM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
KTTA TTM Op. Margin: 0.0%
CLYM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KTTA vs CLYM. Trailing 12-month operating profitability (KTTA 0.0% vs CLYM 0.0%) and valuation multiples (KTTA N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | KTTA | CLYM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $17.7M | $545.1M | Larger Scale | CLYM |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +1498.1% | +0.0% | Higher Growth | KTTA |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -88.8% | -29.3% | Higher ROE | CLYM |
| 52-Week Range Position Momentum | 11% ($0โ$2) | 45% ($2โ$18) | Stronger Trend | CLYM |
| Beta / 30D Volatility Risk Regime | 0.68ฮฒ ยท 185% Vol | 1.42ฮฒ ยท 106% Vol | Lower Realized Risk | CLYM |
| Unified Institutional Score Composite Signal | 42.1 / 100 (HOLD) | 43.7 / 100 (HOLD) | Higher Composite | CLYM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full KTTA vs CLYM Buy Guide
KTTA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CLYM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither KTTA nor CLYM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.